Author(s): Rosaria Alba Merendino | Giuseppe Di Pasquale | Filippo De Luca | Laura Di Pasquale | Edoardo Ferlazzo | Gabriella Martino | Maura Carmela Palumbo | Fortunato Morabito | Sebastiano Gangemi
Journal: Mediators of Inflammation
ISSN 0962-9351
Volume: 13;
Issue: 3;
Start page: 205;
Date: 1992;
Original page
Keywords: Moderate-severe depression | fractalkine | Macrophage inflammatory protein-1 alpha | Serum.
ABSTRACT
MODERATE-severe depression (MSD) is linked to overexpression of proinflammatory cytokines and chemokines. Fractalkine (FKN) and macrophage inflammatory protein-1 alpha (MIP-1α) are, respectively, members of CX3C and C-C chemokines, and both are involved in recruiting and activating mononuclear phagocytes in the central nervous system. We analysed the presence of FKN and MIP-1α in sera of untreated MSD patients and healthy donors. High FKN levels were observed in all MSD patients as compared with values only detectable in 26% of healthy donors. MIP-1α was measurable in 20% of patients, while no healthy donors showed detectable chemokine levels. In conclusion, we describe a previously unknown involvement of FKN in the pathogenesis of MSD, suggesting that FKN may represent a target for a specific immune therapy of this disease.
Journal: Mediators of Inflammation
ISSN 0962-9351
Volume: 13;
Issue: 3;
Start page: 205;
Date: 1992;
Original page
Keywords: Moderate-severe depression | fractalkine | Macrophage inflammatory protein-1 alpha | Serum.
ABSTRACT
MODERATE-severe depression (MSD) is linked to overexpression of proinflammatory cytokines and chemokines. Fractalkine (FKN) and macrophage inflammatory protein-1 alpha (MIP-1α) are, respectively, members of CX3C and C-C chemokines, and both are involved in recruiting and activating mononuclear phagocytes in the central nervous system. We analysed the presence of FKN and MIP-1α in sera of untreated MSD patients and healthy donors. High FKN levels were observed in all MSD patients as compared with values only detectable in 26% of healthy donors. MIP-1α was measurable in 20% of patients, while no healthy donors showed detectable chemokine levels. In conclusion, we describe a previously unknown involvement of FKN in the pathogenesis of MSD, suggesting that FKN may represent a target for a specific immune therapy of this disease.
